These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 26359256)

  • 41. Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Humbert O; Riedinger JM; Charon-Barra C; Berriolo-Riedinger A; Desmoulins I; Lorgis V; Kanoun S; Coutant C; Fumoleau P; Cochet A; Brunotte F
    Clin Cancer Res; 2015 Dec; 21(24):5460-8. PubMed ID: 26130460
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer.
    Humbert O; Riedinger JM; Vrigneaud JM; Kanoun S; Dygai-Cochet I; Berriolo-Riedinger A; Toubeau M; Depardon E; Lassere M; Tisserand S; Fumoleau P; Brunotte F; Cochet A
    J Nucl Med; 2016 Nov; 57(11):1707-1712. PubMed ID: 27103025
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment.
    Herrmann K; Buck AK; Schuster T; Junger A; Wieder HA; Graf N; Ringshausen I; Rudelius M; Wester HJ; Schwaiger M; Keller U; Dechow T
    J Nucl Med; 2011 May; 52(5):690-6. PubMed ID: 21498532
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Breast Cancer Blood Flow and Metabolism on Dual-Acquisition
    Humbert O; Lasserre M; Bertaut A; Fumoleau P; Coutant C; Brunotte F; Cochet A
    J Nucl Med; 2018 Jul; 59(7):1035-1041. PubMed ID: 29439010
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
    Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M
    Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Integrated
    Cho N; Im SA; Cheon GJ; Park IA; Lee KH; Kim TY; Kim YS; Kwon BR; Lee JM; Suh HY; Suh KJ
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):328-339. PubMed ID: 29101445
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Utility of MRI and PET/CT after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity.
    Kim T; Kang DK; An YS; Yim H; Jung YS; Kim KS; Kang SY; Kim TH
    Acta Radiol; 2014 May; 55(4):399-408. PubMed ID: 23963151
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 3'-Deoxy-3'-
    Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.
    Groheux D; Biard L; Lehmann-Che J; Teixeira L; Bouhidel FA; Poirot B; Bertheau P; Merlet P; Espié M; Resche-Rigon M; Sotiriou C; de Cremoux P
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1279-1288. PubMed ID: 29616304
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response.
    Benz MR; Czernin J; Allen-Auerbach MS; Dry SM; Sutthiruangwong P; Spick C; Radu C; Weber WA; Tap WD; Eilber FC
    Cancer; 2012 Jun; 118(12):3135-44. PubMed ID: 22020872
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Value of
    Tatar G; Özkul Ö; Alçin G
    Mol Imaging Radionucl Ther; 2022 Jun; 31(2):123-129. PubMed ID: 35770978
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
    Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
    J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment.
    Groheux D; Giacchetti S; Hatt M; Marty M; Vercellino L; de Roquancourt A; Cuvier C; Coussy F; Espié M; Hindié E
    Br J Cancer; 2013 Sep; 109(5):1157-64. PubMed ID: 23942075
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multiparametric Evaluation of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer Using Integrated PET/MR.
    Wang J; Shih TT; Yen RF
    Clin Nucl Med; 2017 Jul; 42(7):506-513. PubMed ID: 28481792
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of interim 18F-FDG PET/CT in predicting early response to neoadjuvant chemotherapy in breast cancer.
    Pahk K; Rhee S; Cho J; Seo M; Lee S; Park T; Park S; Lee E; Park KH; Kim C; Eo JS; Kim S; Choe JG
    Anticancer Res; 2014 Aug; 34(8):4447-55. PubMed ID: 25075084
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
    Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 18F-FDG or 3'-deoxy-3'-18F-fluorothymidine to detect transformation of follicular lymphoma.
    Wondergem MJ; Rizvi SN; Jauw Y; Hoekstra OS; Hoetjes N; van de Ven PM; Boellaard R; Chamuleau ME; Cillessen SA; Regelink JC; Zweegman S; Zijlstra JM
    J Nucl Med; 2015 Feb; 56(2):216-21. PubMed ID: 25593118
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.
    Eckel F; Herrmann K; Schmidt S; Hillerer C; Wieder HA; Krause BJ; Schuster T; Langer R; Wester HJ; Schmid RM; Schwaiger M; Buck AK
    J Nucl Med; 2009 Sep; 50(9):1441-7. PubMed ID: 19690030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.